- Home
- VOR vs ENTA Comparison
VOR vs ENTA Comparison
Compare VOR & ENTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VOR
- ENTA
- Stock Information
- Founded
- VOR 2015
- ENTA 1995
- Country
- VOR United States
- ENTA United States
- Employees
- VOR N/A
- ENTA N/A
- Industry
- VOR Biotechnology: Pharmaceutical Preparations
- ENTA Biotechnology: Pharmaceutical Preparations
- Sector
- VOR Health Care
- ENTA Health Care
- Exchange
- VOR Nasdaq
- ENTA Nasdaq
- Market Cap
- VOR 202.4M
- ENTA 164.6M
- IPO Year
- VOR 2021
- ENTA 2013
- Fundamental
- Price
- VOR $2.30
- ENTA $6.96
- Analyst Decision
- VOR Buy
- ENTA Buy
- Analyst Count
- VOR 7
- ENTA 4
- Target Price
- VOR $3.77
- ENTA $18.00
- AVG Volume (30 Days)
- VOR 47.3M
- ENTA 147.9K
- Earning Date
- VOR 08-07-2025
- ENTA 08-04-2025
- Dividend Yield
- VOR N/A
- ENTA N/A
- EPS Growth
- VOR N/A
- ENTA N/A
- EPS
- VOR N/A
- ENTA N/A
- Revenue
- VOR N/A
- ENTA $64,462,999.00
- Revenue This Year
- VOR N/A
- ENTA N/A
- Revenue Next Year
- VOR N/A
- ENTA $0.48
- P/E Ratio
- VOR N/A
- ENTA N/A
- Revenue Growth
- VOR N/A
- ENTA N/A
- 52 Week Low
- VOR $0.13
- ENTA $4.09
- 52 Week High
- VOR $3.29
- ENTA $17.24
- Technical
- Relative Strength Index (RSI)
- VOR 78.77
- ENTA 46.80
- Support Level
- VOR $2.25
- ENTA $6.50
- Resistance Level
- VOR $3.29
- ENTA $8.23
- Average True Range (ATR)
- VOR 0.52
- ENTA 0.42
- MACD
- VOR 0.18
- ENTA -0.15
- Stochastic Oscillator
- VOR 82.52
- ENTA 26.62
About VOR Vor Biopharma Inc.
Vor Biopharma Inc is a clinical stage cell therapy company. It combines a novel patient engineering approach with targeted therapies to provide a solution for patients suffering from hematological malignancies. The company's products include VCAR33, Tremcel and Myelodysplastic Syndrome, Trem-cel+VCAR33 Treatment System, VADC45, CD123, CLL1, EMR2.
About ENTA Enanta Pharmaceuticals Inc.
Enanta Pharmaceuticals Inc is an American biotechnology company which uses robust, chemistry-driven approach and drug discovery capabilities to focus on the research and development of molecule drugs to cure viral infections and liver diseases. Uses virology and immunology method for curing the diseases. The targeted diseases are hepatitis C, hepatitis B, nonalcoholic steatohepatitis, and the respiratory syncytial virus. The novelty of company research is a specific direct-acting antiviral inhibitor against the hepatitis C virus. The company's inhibitors have been developed in collaboration with AbbVie. AbbVie markets the protease inhibitor, paritaprevir, while other inhibitors are in the pipeline.